Browsing Department of Clinical Medicine by Author "Gavasso, Sonia"
Now showing items 1-4 of 4
-
Deficient phosphorylation of stat-1 in leukocytes identifies neutralizing antibodies in multiple sclerosis patients treated with interferon-beta
Gavasso, Sonia; Mosleth, Ellen Færgestad; Marøy, Tove Helene; Jørgensen, Katarina Mariann; Nakkestad, Hanne Linda; Gjertsen, Bjørn Tore; Myhr, Kjell-Morten; Vedeler, Christian A. (Peer reviewed; Journal article, 2014-02-19)Background: Anti interferon-beta (IFN-β) neutralizing antibodies (NAb) affect efficacy of treatment of multiple sclerosis patients, but exactly when the detrimental effects of NAbs offset therapeutic efficacy is debated. ... -
Optimization of receptor occupancy assays in mass cytometry: Standardization across channels with QSC beads
Bringeland, Gerd Haga; Bader, Lucius; Blaser, Nello; Budzinski, Lisa; Schulz, Axel R.; Mei, Henrik E.; Myhr, Kjell-Morten; Vedeler, Christian A.; Gavasso, Sonia (Peer reviewed; Journal article, 2019)Receptor occupancy, the ratio between amount of drug bound and amount of total receptor on single cells, is a biomarker for treatment response to therapeutic monoclonal antibodies. Receptor occupancy is traditionally ... -
Wearing-off at the end of natalizumab dosing interval and risk of MS disease activity: A prospective 1-year follow-up study
Bringeland, Gerd Haga; Myhr, Kjell-Morten; Vedeler, Christian A.; Gavasso, Sonia (Journal article; Peer reviewed, 2020)Natalizumab effectively prevents disease activity in relapsing-remitting multiple sclerosis by binding α4 integrin and inhibiting leukocyte migration to the central nervous system. We recently reported an association between ... -
Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy
Bringeland, Gerd Haga; Blaser, Nello; Myhr, Kjell-Morten; Vedeler, Christian A.; Gavasso, Sonia (Journal article; Peer reviewed, 2020-02)Objective: We aimed to investigate whether wearing-off symptoms at the end of the natalizumab dosing interval were associated with clinical and demographic patient characteristics or natalizumab receptor occupancy (RO) on ...